Advocacy & PolicyFDA Response to Citizen Petition to the FDA and ATTUD & SRNT Follow-up Letter to FDA regarding Nicotine Replacement Therapy Labeling: The Food and Drug Administration (FDA) is announcing that we have concluded that certain statements set forth in the FDA-approved labels of over-the-counter nicotine replacement therapy products, related to concomitant use with other nicotine-containing products and duration of use, can be modified. In light of currently available evidence, these statements are no longer believed to be necessary in their current form to ensure the safe and effective use of over-the-counter nicotine replacement therapy products for their approved intended use as aids to smoking cessation.”
ATTUD Letter to FDA to provide rationale and advocate for restricting the use of menthol in cigarettes: Tobacco Products Scientific Advisory Committee’s (TPSAC) Report on Use of Menthol in Cigarettes
A white paper developed by the ATTUD disparities committee to provide rationale for the integration of tobacco dependence treatment within behavioral health settings
ATTUD Letter to Joint Commission in support of widespread endorsement of the new tobacco use measures: Proposed Tobacco Treatment Measures for Hospitalized Smokers.
The New York state Tobacco Education Task Force Recommendations in support of more tobacco dependence and treatment content to be on physician exams in 2014; which were accepted by the U.S. Medical Licensing Board.
Letter to PA Dept of Public Welfare requesting that Medicaid patients have access to all 7 FDA approved tobacco treatment medications
The Truth Tobacco Industry Documents is an archive of 14 million documents created by tobacco companies about their advertising, manufacturing, marketing, scientific research and political activities, hosted by the UCSF Library and Center for Knowledge Management. |